PURPOSE The objective of this review was to address the barriers limiting access to genetic cancer risk assessment and genetic testing for individuals with suspected hereditary breast and ovarian cancer (HBOC) through a review of the diagnosis and management steps of HBOC.
INTRODUCTION
Approximately 10% and 25% of all breast (BC) and ovarian cancers (OC), respectively, are hereditary. 1 Identification of pathogenic germline variants in high-/moderate-penetrance cancer-predisposing genes allows the implementation of strategies for cancer risk reduction and early detection. In Brazil, there is limited access to cancer risk assessment and genetic testing for individuals with suspected hereditary cancer, as well as limited information on its burden in the country. Therefore, the objective of this study was to make harmonized recommendations for improving early detection, risk management, and cancer care of patients with hereditary breast and ovarian cancer (HBOC).
METHODOLOGY
The Americas Health Foundation convened a 6member panel of clinical and scientific experts in oncology, gynecology, genetics, and applied genomics from Brazil. PubMed and Embase were used to conduct a literature review and to identify Brazilian experts who have published in the field of HBOC since 2012. To better focus the discussion, Americas Health Foundation staff developed specific questions for the panel to address. A written response to each question was drafted by each expert and was discussed during a multiday meeting. Questions were edited by the entire group, through numerous drafts and rounds of discussion, until complete consensus was obtained.
BURDEN AND EPIDEMIOLOGY OF, AND RISK FACTORS FOR, HBOC
HBOC is a highly penetrant, autosomal dominant disorder mostly caused by pathogenic and likely pathogenic germline variants in BRCA1 and BRCA2 genes. 1 BRCA1 and BRCA2 are tumor suppressor genes that repair double-stranded DNA breaks through homologous recombination (HR). 2 Individuals harboring germline pathogenic variants in BRCA1 and BRCA2 are predisposed to BC (lifetime risk up to 85% and 45%, respectively) and OC (lifetime risk up to 39% and 11%, respectively), as well as other malignancies. [3] [4] [5] The population prevalence of BRCA1 and BRCA2 pathogenic variants is 1:150-1:200 individuals in North American and European populations. 6 Mutation prevalence varies according to ethnicity, the genetic testing criteria used, age at cancer diagnosis, and family history. The catalog of germline variants in BRCA genes in different populations should be expanded and made available in public databases such as ClinVar and BRCA Challenge.
BC and OC risks may be increased by pathogenic variants in other high-penetrance (TP53, PTEN, STK11, CDH1, and PALB2) and moderate-penetrance (CHEK2, ATM, NF1, RAD51C, RAD51D, and BRIP1) genes. The American College of Medical Genetics has recognized 25 actionable genes for which there is enough evidence to implement an effective cancer risk-reduction strategy. 7 Cancer risk management has been implemented in BRCA1 and BRCA2 pathogenic carriers, whereas knowledge about the appropriate management of carriers with moderate-penetrance genes is still limited. 8 Multigene panel testing, including actionable genes related to BC and OC, may be considered for patients who fulfill the clinical criteria for HBOC. 9 Testing only BRCA genes may miss approximately one-half of the pathogenic germline variants involved in HBOC risk, 10 and next-generation sequencing allows testing genes with clinical usefulness at an affordable cost. 9, 11, 12 Panel testing should be recommended only by trained physicians to ensure adequate genetic counseling and management. There is no added value of exome and whole-genome testing in HBOC families, and this should not be recommended. Treatmentfocused genetic testing (TFGT) and genomic tumor profiling are currently the gold standard in defining better treatment strategies for tumors such as ovarian serous carcinomas. This generates an urgent need to provide more effective, timely, and adequate pre-and post-test genetic counseling. 13 Several genetic and environmental factors can modulate the penetrance of germline BRCA1 and BRCA2 pathogenic variants. Variant location, with the identification of clusters of mutations with differential cancer risks, may be associated with higher BC or OC risks. 14 In addition, several genetic variants have been identified in coding and noncoding regions, which may modulate the penetrance of germline BRCA1/2 variants, such as those described by the Consortium of Investigators of Modifiers of BRCA1/2. 15 Risk-protecting factors (eg, breast feeding in BRCA1 carriers) and risk-enhancing factors (eg, obesity) have been identified (Appendix Table A1 ). Studies on cancer risk modifiers in Brazilian patients with HBOC are not currently available. Such studies are needed to verify whether these cancer risk modifiers have a role in risk management strategies tailored to Brazil's admixed population.
MOLECULAR EPIDEMIOLOGY OF HBOC
In the mutational landscape of BRCA1 and BRCA2 variants in . 29,000 families 16 substantial variation in mutation type and frequency by geographical region and race/ethnicity was observed. Recurrent germline BRCA variants have been described in specific populations or geographic regions, and some are caused by founder effects (Table 1) . In these situations, mutation-specific screening strategies are efficient, such as the 3 BRCA1 and BRCA2 Ashkenazi founder mutations identified in 2.5% of this population. 13 Nine studies have performed comprehensive BRCA mutation testing in 2,090 individuals from high-risk cohorts in Brazil. [17] [18] [19] [20] [21] [22] [23] [24] [25] Mutation prevalence estimates in individuals with clinical criteria are 19%-22%. 26, 27 Approximately 5% are large gene rearrangements. Certain variants are specific to Brazilian regions as a result of distinctive patterns of immigration in the past centuries. 28, 29 HEREDITARY BC RELATED TO TP53 GENE In Brazil, a significant percentage of BC burden is conferred by Li-Fraumeni syndrome (LFS), because of a founder mutation, TP53 p.Arg337His (p.R337H)(NC_000017.9: c.1010G.A), present in 0.3% of the southern and southeastern populations. LFS has a wide tumor spectrum, predisposing to premenopausal BC, sarcomas, brain tumors, and adrenocortical carcinoma, among other cancers. 30 Strong evidence supports the association between the TP53 germline variant and a worse overall and disease-free survival in BC. [31] [32] [33] In classic LFS, cancer risk CONTEXT Key Objective How can the diagnosis and management of hereditary breast and ovarian cancer be improved in Brazil? A panel of Brazilian experts proposes recommendations for improving access to early diagnosis, risk management, and cancer care of hereditary breast and ovarian cancer. Knowledge Generated Understanding Brazil's unique social and structural barriers is crucial to expanding access to genetic cancer risk assessment.
Government, medical societies, patient organizations, academic centers, and the private sector should collaborate to create a multistakeholder commission to develop and promote the incorporation of genetic cancer risk assessment. Relevance Increased knowledge and awareness, together with regulatory actions to expand hereditary cancer testing and counseling in Brazil, have the potential to improve the care of patients with cancer and reduce the cancer burden across the country. No Also recurrent in Hispanic populations, Europe, USA, and the UK by age 60 years is 90% in women and 73% in men, with an overall cumulative incidence of 50% by age 40 years. 34, 35 The p.R337H TP53 variant confers a lifetime cancer risk that differs from typical DNA-biding domain TP53 pathogenic variants. Carriers have a lifetime cancer risk of 80% in females, and 47% in males. 36 BC is the most common malignancy diagnosed in LFS. In p.R337H carriers, the mean age is 40 years, and in classic LFS, 32 years. 37 In a cohort of 815 women affected by BC in southern Brazil who developed the disease before age 45 years, the result was a high prevalence of the p.R337H (12.1%). 38 These results suggest that inheritance of p.R337H may contribute to a significant number of BC cases in Brazil.
Currently, in Brazil, genetic testing for TP53 mutation is for families who fulfill certain criteria, which may include all cases of BC below age 35 years, regardless of family history. 27, 39 Recent studies suggested that all women with premenopausal BC in Brazil should be tested for p.R337H. 40, 41 Effective screening strategies for LFS represent a major challenge because of the wide spectrum of tumors and the variable ages of onset. Given the suspected high population prevalence of the founder mutation in Brazil, and the public health issue it may constitute, a better knowledge of its country-wide prevalence, as well as the effective management of costeffective strategies dedicated to the Brazilian population, are urgently required.
DIAGNOSIS, MANAGEMENT, COST EFFECTIVENESS, AND TREATMENT OPTIONS IN HBOC IN BRAZIL
Genetic cancer risk assessment (GCRA) is an interdisciplinary medical practice that identifies, counsels, and manages individuals and families at high risk of an inherited cancer syndrome. 42 In Brazil, access to GCRA and consequent management options according to established risk are limited. Improving access is essential to increase health and improve cancer outcomes.
Although genetic testing is not available in the Brazilian public health care system, in the private system, coverage is available for molecular testing in individuals who fulfill criteria established by the Agencia Nacional de Saude. 27 Agencia Nacional de Saude guidelines include riskreducing interventions for carriers of a pathogenic germline variant (eg, risk-reducing surgeries, breast reconstruction, and access to follow-up breast magnetic resonance imaging [MRI] in patients who decline surgery). Meeting the need for adequate post-test counseling is a challenge. Regulatory actions and policy recommendations are urgently needed to address these issues. Table 2 lists the recommendations of this panel in defining criteria for genetic testing for individuals with HBOC in Brazil.
Women diagnosed with BC or OC may be offered TFGT, with targeted therapies for BRCA carriers. As the demand for TFGT increases, alternative models of providing information to patients before genetic testing should be sought, because there is a limited number of genetic risk assessment providers. A streamlined approach may be an effective solution. It relies on substituting traditional pretest genetic counseling with providing information, the graphic/ visual information to the patient, or focused counseling by the treating physician. [43] [44] [45] UNDERSTANDING GENETIC TESTING RESULTS
In the presence of germline BRCA1/BRCA2 and TP53 variants, current options for risk reduction and early detection include surveillance and risk-reducing surgeries. In individuals without a previously identified pathogenic variant, the absence of a pathogenic variant cannot definitively exclude hereditary cancer, because some individuals may still harbor an elevated risk of HBOC caused by unknown/unidentified genetic risk factors. In this scenario, models estimating cancer risk on the basis of family history and individual risk factors should be communicated to the patient. It is important to investigate both maternal and paternal lineages to prevent missing additional cancer risk.
Whenever a variant of uncertain significance (VUS) is identified, this result must be considered inconclusive and no clinical action is justified. The Brazilian population is highly admixed, and there is likely an increased prevalence of VUS. Nevertheless, preliminary data have shown a prevalence similar to those of North American and European populations. 23 The majority (. 90%) of VUS will be reclassified to benign or likely benign categories. 46 Nevertheless, VUS should always be reported and periodically reassessed. Reaching back to patients regarding new, updated testing options or techniques should also be ensured. 42, [46] [47] [48] [49] 
MANAGEMENT OPTIONS
Because of a lack of local studies, all recommendations for Brazil are based on international data. Although surveillance strategies for moderate-penetrance genes have limited data, some screening strategies must be encouraged (Table 3) .
Intensive Surveillance for BRCA1 and BRCA2 Carriers
An annual breast MRI in conjunction with annual mammography screening in BRCA1 and BRCA2 carriers from the age of 30 years is more sensitive than annual mammography alone, detecting BC at an earlier stage. [50] [51] [52] [53] [54] MRI screening every 6 months has shown optimal performance for women at risk of BRCA1-associated BC. 55 Although in Brazil these resources are not sufficiently well distributed, breast MRI is fully covered for patients who carry a BRCA pathogenic variant. 27 Additional studies to determine the combination of screening modalities, potential harms of exposure to mammography radiation, cost effectiveness, and survival are needed. 56, 57 Future perspectives in this field include the adoption of abbreviated MRI protocols and the use of less contrast to reduce costs. 58, 59 OC screening is not recommended. However, in patients who decline riskreducing salpingo-oophorectomy, transvaginal ultrasound and serum CA-125 may be considered, at the clinician's discretion.
Risk-Reducing Bilateral Mastectomy for BRCA1 and BRCA2 Carriers
Bilateral mastectomy is associated with . 90% risk reduction in BC. 60 In BRCA1 and BRCA2 carriers, nipplesparing mastectomy is associated with a low rate of complications. 61, 62 Surveillance strategies after riskreducing mastectomy are not well established and should be addressed on a case-by-case basis. A recent study showed that bilateral risk-reducing mastectomy in mutation carriers had an impact on mortality in BRCA1 carriers, although the impact in BRCA2 carriers was less evident. 63 Contralateral Risk-Reducing Mastectomy for BRCA1 and BRCA2 Carriers
Cumulative contralateral BC risk 20 years after a first primary BC is 40% for BRCA1 and 26% for BRCA2 carriers. Current evidence suggests that contralateral risk-reducing mastectomy is effective for BRCA1 carriers, reducing mortality. [64] [65] [66] [67] Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA1 and BRCA2 Carriers
Bilateral salpingo-oophorectomy (BSO) confers a 72%-88% risk reduction in OC and fallopian tubal cancer. It is associated with a reduction in OC-specific and all-cause mortality in BRCA carriers. 60 individualized, on the basis of the age of onset of OC in the family. Detailed sectioning and microscopic examination of ovaries and fallopian tubes from BSO in high-risk populations led to the identification of occult carcinomas in up to 1.9%-9.1% of cases. 60 After risk-reducing surgery, there is a 10% risk of recurrence after detection of an occult carcinoma and a 1% risk of developing a primary peritoneal tumor. 69 Early surgical castration causes early menopause and increases the risk of cardiovascular disease and osteoporosis. On the basis of available data from observational studies, hormone replacement therapy after BSO should not be performed in patients affected by BC, but it has not shown an increased risk of BC among cancer-free BRCA carriers who have undergone risk-reduction bilateral mastectomy. 70 Chemoprevention for BRCA1 and BRCA2 Carriers
Large primary prevention trials with tamoxifen, 20 mg once per day for 5 years, have demonstrated that BC risk can be reduced by 40%-50% in women at high risk, although not necessarily in pathogenic variant carriers. 71 Limited data are available regarding the benefit of tamoxifen in BRCA carriers, but it may be considered for patients who do not want to undergo risk-reducing surgery. 72, 73 There are no data on the benefit of raloxifene or aromatase inhibitors in BRCA carriers.
PolyADP-Ribose Polymerases in BRCA-Associated OC for BRCA1 and BRCA2 Carriers
PolyADP-ribose polymerases (PARP) inhibitor is a targeted therapy that acts on a deficiency in the HR pathway. In OC, 2 randomized phase III trials (SOLO-2 and NOVA) demonstrated improved progression-free survival with monotherapy PARP inhibitor as maintenance therapy in patients with recurrent, platinum-sensitive BRCAassociated OC and HR-deficient tumors. 74, 75 In first-line treatment, SOLO-1 showed better progression-free survival with PARP inhibitor (olaparib) maintenance treatment after usual chemotherapy in BRCA-associated stage III-IV highgrade serous or endometrial OC. 76 Agência Nacional de Vigilância Sanitária has approved olaparib for relapsed high-grade OC and for first-line BRCA-associated serous and endometrioid high-grade OC, but it is not yet available to the public or in the private health system.
PARP Inhibitor in BRCA-Associated BC for BRCA1 and BRCA2 Carriers
Two phase III trials (OlympiAD and EMBRACA) randomly assigned patients after chemotherapy in HER2-negative, BRCA-associated metastatic BC and showed longer progression-free survival with PARP inhibitor. The Food and Drug Administration has approved 2 PARP inhibitors (olaparib 77 and talazoparib 78 ) for germline BRCAassociated metastatic BC. In Brazil, olaparib was approved in this setting by Agência Nacional de Vigilância Sanitária in 2018.
MANAGEMENT OPTIONS FOR TP53 GERMLINE PATHOGENIC VARIANT CARRIERS
All carriers of a TP53 pathogenic variant should receive intensive surveillance. In Brazil, because of the founder variant present in a significant part of the population, management is a public health situation that remains unresolved. Nevertheless, breast MRI should be offered annually from age 20 years and mammography annually after age 30 years. Risk-reducing bilateral mastectomy and contralateral risk-reducing mastectomy should be suggested. Whole-body MRI and brain MRI should be performed yearly from birth in carriers because of the high risk of sarcomas and CNS, adrenocortical, and other tumors.
COST-EFFECTIVENESS OF GENETIC TESTING
BRCA testing is cost effective in BC and OC. It is associated with reduced risk and improved survival in female carriers, with benefits when testing is extended to family members (cascade testing). 79, 80 Presymptomatic cancer surveillance is cost effective for patients with germline pathogenic variants in TP53. 81 Risk-reduction surgery and intensive breast screening were cost effective in models of BRCA carrier risk management. 82 In Brazil, BRCA1/BRCA2 diagnostic and management strategies for patients with OC were considered cost effective but only when cancer-unaffected relatives of OC mutation carriers were included in the model. 83 
CURRENT BARRIERS AND RECOMMENDATIONS FOR OVERCOMING BARRIERS TO ADEQUATE DIAGNOSIS AND MANAGEMENT OF HBOC IN BRAZIL
Despite evidence of the benefits of genetic counseling, testing, and adequate risk management, 42 access is limited in Brazil and in most Latin American countries (Table 4 ). To address these limitations, strategies related to public awareness, education, integrated services, implementation, and monitoring are needed. Government, medical societies, patient organizations, academic centers, and the private sector should create a multistakeholder commission to develop and promote the incorporation of GCRA and management into the public and private health care systems. Such a plan should include the following: 
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